Here are five things to know:
1. In the INSPIRE study, seven of the 16 patients — 44 percent — who reached the six-month primary endpoint visit had an ASIA Impairment Scale conversion at six months after implantation. The objective performance criterion for the study was a 25 percent AIS conversion rate based on the published conversion rates for thoracic SCI.
2. All patients evaluated at the 12-month follow-up mark who had converted an AIS grade at the sixth-month visit remained converted.
3. In total, 19 patients were implanted with the investigational Neuro-Spinal Scaffold in the INSPIRE study.
4. InVivo has officially closed the INSPIRE study and received FDA supplemental investigational device exemption approval for a second clinical study of the Neuro-Spinal Scaffold in patients with acute SCI. INSPIRE 2.0 will include 20 patients and is intended to enhance the existing clinical evidence.
5. The Neuro-Spinal Scaffold is a bioresorbable polymer scaffold designed for implantation at the site of injury within a spinal cord contusion. It is engineered to provide structural support to the spared spinal tissue and a supportive matrix to encourage endogenous repair processes. The scaffold degrades over several weeks.
More articles on biologics:
Organogenesis to merge to create $673M company: 4 notes
6 things to know about Isto Biologics
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
